SPEAKER_00 0:00

So I want you to imagine for just a second that you are, well, a detective.

SPEAKER_01 0:04

Okay.

SPEAKER_00 0:04

But instead of trying to solve a crime in, you know, some dark alley somewhere, you're actually trying to solve a medical mystery.

SPEAKER_01 0:11

Right. The stakes are a bit different.

SPEAKER_00 0:12

Exactly. And here is the major catch for this mystery. The fingerprints left behind by your prime suspect, they actually change.

SPEAKER_01 0:21

Oh, wow.

SPEAKER_00 0:22

Yeah. They change depending on the suspect's age, depending on their stress levels on any given day, and um even depending on what blood type they have.

SPEAKER_01 0:30

I mean, when the evidence itself is constantly shifting shape like that, building a reliable profile seems, frankly, nearly impossible. You'd be forced to question the very nature of the clues you're collecting.

SPEAKER_00 0:40

Right. And that shifting, almost liquid landscape is exactly what we are exploring in today's deep dive. We are looking at this really fascinating essay. It's titled Classification at the Border by William Ayrd.

SPEAKER_01 0:52

It's a great piece.

SPEAKER_00 0:53

It really is. Yeah. And our mission today is to explore how the field of medicine handles these massive, murky gray areas. Specifically, we're going to look at this through the lens of diagnosing a bleeding disorder called von Willebrand disease, or uh VWD.

SPEAKER_01 1:10

Yeah. And what Ayard does in this essay is he really examines what happens when human biology just absolutely refuses to fit into our nice neat diagnostic checkboxes. Right. He establishes the central thesis that really anchors the entire discussion we're about to have. He states, at the center, classification names mechanism. At the border, classification organizes probability.

SPEAKER_00 1:31

Okay, I love that quote. And I want to speak directly to you, the listener, right now. Because whether you are, you know, a seasoned medical professional navigating these exact issues, or maybe someone dealing with a baffling health mystery of your own, or just an insanely curious learner who loves a good paradigm shift, this deep dive is going to completely alter how you view a medical diagnosis.

SPEAKER_01 1:51

Oh, absolutely.

SPEAKER_00 1:52

Because we are conditioned to think of a diagnosis as a binary, right? Right. Broken or not broken, sick or healthy. But a diagnosis is often um a continuous gradient.

SPEAKER_01 2:04

It is. And to really understand how murky and complex that gradient gets at the border, we first need to start by looking at the center.

SPEAKER_00 2:12

Makes sense.

SPEAKER_01 2:13

We have to look at the cases where medical classification works exactly as it was intended to.

SPEAKER_00 2:18

Okay, let's unpack this a bit. In my mind, diagnosing these central clear-cut cases, it's like a mechanic diagnosing a car that has, say, no engine. Right. Or a car where the steering wheel is completely detached from the dashboard. The failure's obvious, it's discrete, and the diagnosis tells you exactly what part you need to order.

SPEAKER_01 2:37

That's a perfect analogy. Yeah. What's fascinating here is that at the mechanistic center of von Willebrand disease, the subtype label a doctor assigns, it perfectly names a recognizable structural biological failure.

SPEAKER_00 2:48

So it's not a guess.

SPEAKER_01 2:49

No, not at all. The label isn't a guess, it's a pinpoint description of a broken part. For example, let's look at type three VWD. In type three, there is a near-complete absence of von Willebrand factor or VWF. The engine is simply gone.

SPEAKER_00 3:03

Right. And VWF is a crucial blood clotting protein. If we think of blood platelets as like the bricks that build a clot to stop bleeding, VWF is the mortar or the glue.

SPEAKER_01 3:14

Exactly, it's the glue. So in type three, there is no glue, so there is no clotting. It's just an absolute deficiency. But then we move into the type 2 variants where the protein is present, but it's structurally defective.

SPEAKER_00 3:25

So the engine is there, but it's busted.

SPEAKER_01 3:27

Yes. Take type 2N, for instance. The VWF is there, but its specific binding site for another really crucial clotting protein, factor 8, is broken.

SPEAKER_00 3:35

Wait, so it can't carry factor 8 at all?

SPEAKER_01 3:38

Right. And because it can't carry factor 8, this variant actually mimics a completely different bleeding disorder, which is hemophilia A.

SPEAKER_00 3:45

Oh wow. So the label literally tells the clinician the exact blueprint of the failure.

SPEAKER_01 3:50

Precisely. Now let's look deeper into the structural mechanics, specifically something called multimers.

SPEAKER_00 3:56

Multimers, okay.

SPEAKER_01 3:57

Because VWF doesn't just float around as single tiny molecules. To work properly in the fast-flowing environment of your bloodstream, it has to assemble into these massive, heavy chains of sticky molecular hooks. Those massive chains are the multimolkers.

SPEAKER_00 4:13

Okay, so it's like linking 100 carabiners together to make a heavy-duty toe cable.

SPEAKER_01 4:18

I like that, yes, a heavy-duty toe cable. So in type 2a, the body fails to build or maintain those massive chains. It's a loss of the high molecular weight multimers, which directly compromises how well platelets can adhere to one another under the intense sheer stress of flowing blood.

SPEAKER_00 4:35

Aaron Powell The co-cable essentially snaps.

SPEAKER_01 4:37

Exactly. Then you have type 2M. In this one, the massive multimultrains are relatively preserved, but the adhesive function itself is impaired.

SPEAKER_00 4:45

So the hooks are dull, the glue has lost its stickiness.

SPEAKER_01 4:48

You've got it. Which brings us to, honestly, the strangest one on the list, type 2B.

SPEAKER_00 4:53

Aaron Powell Right, because this one is a paradox, right? The mechanism isn't failing by being weak, it's failing by being um too aggressive.

SPEAKER_01 5:00

Aaron Powell Yeah. Type 2B is a classic again of function mutation. The VWF binds to the specific docking station on the blood platelet, a receptor called GPI alpha, but it binds far too avidly.

SPEAKER_00 5:11

Like it just grabs hold immediately.

SPEAKER_01 5:13

Right. Before there is even an injury to respond to. And because these massive chains of VWF are clumping with platelets prematurely in the bloodstream, the body's cleanup crew comes along and clears all those clumps out.

SPEAKER_00 5:25

So by working too hard and binding too tightly, it actually depletes the body supply of the largest multimarser.

SPEAKER_01 5:31

Yes.

SPEAKER_00 5:31

And it sweeps away the platelets too, leaving you with a dangerously low platelet count when an actual injury happens.

SPEAKER_01 5:37

Exactly, which is a condition known as thrombocytopenia. The biological machine essentially destroys its own tools. But the main takeaway here is that in all these examples, type 3, 2N, 2A, 2M, 2B, the diagnosis isn't a mystery. Right. In these mechanistic sender settings, the label doesn't merely describe a symptom pattern. It links a name directly to a precise, undeniable biological mechanism.

SPEAKER_00 6:00

Aaron Powell But human biology is rarely a clean collection of discrete, interchangeable parts, right? I mean, if the center is where the engine is missing or the steering column is snapped in half, what happens when the engine is just, I don't know, running a little sluggishly.

SPEAKER_01 6:16

That's where things get complicated.

SPEAKER_00 6:18

Aaron Powell Because the failure isn't structural anymore. It is a matter of degree. And I feel like this pushes us out of that clear-cut center and into what Aired calls the borderland.

SPEAKER_01 6:28

Yeah, welcome to the borderland. This area is populated by patients who don't have a massive, obvious genetic defect. Instead, they just have mildly reduced VWF levels.

SPEAKER_00 6:39

Mildly reduced.

SPEAKER_01 6:40

Right. Specifically, the medical field often looks at the range of 30 to 50 IUDL.

SPEAKER_00 6:45

Aaron Powell Okay. Just to ground that measurement for a moment for everyone listening, IUDL stands for international units per deciliter. And while a baseline normal can vary, a typical population average might hover somewhere around like 100.

SPEAKER_01 6:57

That's right.

SPEAKER_00 6:58

So dropping down into that 30 to 50 range is a significant dip, sure, but it's not a flat line.

SPEAKER_01 7:03

Aaron Powell No, not at all. And it is a borderland because those BWF levels are not static. They vary continuously across the entire population. And the list of modifiers is just staggering.

SPEAKER_00 7:14

Aaron Powell Staggering how?

SPEAKER_01 7:16

Well, your baseline is influenced by genetics, certainly, but it is also influenced by your ABO blood group, your age, whether you have systemic inflammation, your hormonal state, pregnancy, stress, exercise, even other comorbid illnesses, it all changes the number.

SPEAKER_00 7:34

Aaron Powell Wait, if going for a jog, being stressed out at work, or simply having typo blood can change the fingerprint, setting a definitive baseline seems wildly subjective.

SPEAKER_01 7:43

It definitely highlights the challenge.

SPEAKER_00 7:45

I mean, I struggle with the very concept of a hard threshold here. If a diagnostic threshold for this disease is set at 50, does a patient sitting at 49 really have a fundamentally different underlying biology than a patient sitting at 51? Yeah. Nature doesn't build cliffs, right? It builds slopes. Are we just making up these cutoffs to make the paperwork easier?

SPEAKER_01 8:02

The skepticism you're voicing is actually a central tension in modern medicine. Thresholds should never be mistaken for nature itself. A person at 49 is not harboring a disease while a person at 51 is biologically pristine. However, medical systems require lines in the sand.

SPEAKER_00 8:18

Because of logistics.

SPEAKER_01 8:19

Exactly. Clinicians need thresholds to standardize care across thousands of hospitals, to communicate risk objectively, to determine who is eligible for certain hemostatic treatments, and inescapably to navigate insurance coverage.

SPEAKER_00 8:33

Oh, of course, insurance. So how does the medical community reconcile that artificial threshold with the messy biological reality?

SPEAKER_01 8:40

Aaron Powell Well in 2021, a major coalition of the world's leading hematology and hemophilia organizations released updated diagnostic guidelines and they established a two-tiered system to handle this exact borderland.

SPEAKER_00 8:52

Aaron Powell Okay. How does the tier system work?

SPEAKER_01 8:54

They decided that patients with VWF levels severely depressed below 30 IUDL have type 1 VWD, regardless of whether they actively report bleeding symptoms. The number is just low enough to warrant the label outright.

SPEAKER_00 9:06

Okay, that makes sense. But what about the patients hovering in that murky 30 to 50 borderland?

SPEAKER_01 9:10

Aaron Powell For that group, they are diagnosed with type 1 VWD only if they also have a documented history of abnormal bleeding. So the guideline marries the laboratory number with the lived experience of the patient.

SPEAKER_00 9:22

Marrying the number to the real world experience seems super logical, but I imagine establishing that specific threshold ignited a pretty significant debate in the medical field.

SPEAKER_01 9:33

Oh, it triggered a massive ongoing conversation. Setting any threshold in a continuous gradient creates two distinct risks. Which are? On one side of the debate, experts worry this guideline expands the label of type 1 VWD way too far. They argue it risks medicalizing people who merely possess a mild bleeding risk factor rather than a true, clear-cut genetic disease.

SPEAKER_00 9:55

Ah, so overdiagnosis.

SPEAKER_01 9:57

Yes, the fear of overdiagnosis. Giving someone a lifelong disease label along with the psychological anxiety and potential insurance complications for what might just be the lower end of normal biological variation.

SPEAKER_00 10:08

The counterargument being, I assume, that if you tighten the threshold too much, you leave people suffering without any medical support. I mean, telling someone who experiences debilitating heavy bleeding that their lab work says they are, quote unquote, biologically normal does not stop the bleeding.

SPEAKER_01 10:24

Aaron Powell Right. The fear of underdiagnosis is just as critical. Proponents of the 2021 guidelines argue they are vital because they provide validation and access to care for patients. Very often, women experiencing severe heavy menstrual bleeding.

SPEAKER_00 10:38

Because their symptoms have been historically minimized.

SPEAKER_01 10:41

Yes. Minimized, normalized, or entirely dismissed by the medical system for decades. This guideline grants them an official diagnosis so they can actually access hemostatic support therapies.

SPEAKER_00 10:52

Which is life-changing.

SPEAKER_01 10:53

Completely. Both concerns over diagnosis and underdiagnosis are entirely valid reflections of the exact same problem. Thresholds start conversations, they do not end them.

SPEAKER_00 11:03

Here's where it gets really interesting to me, though. If the lab numbers are this volatile and a threshold of 50 is somewhat arbitrary, it shifts an enormous amount of weight onto the patient's real-world history.

SPEAKER_01 11:14

The phenotype, right?

SPEAKER_00 11:15

Exactly, the phenotype.

SPEAKER_01 11:17

But relying on a patient's bleeding history introduces this massive, almost invisible trap into the diagnostic process.

SPEAKER_00 11:26

Yes, the trap of the untested challenge.

SPEAKER_01 11:28

Okay. I want you, the listener, to put yourself in the shoes of a patient, let's say a 10-year-old child.

SPEAKER_00 11:33

Okay.

SPEAKER_01 11:33

They get a routine blood test before a minor procedure, and they have low normal VWF levels, hovering right around 42. The clinician asks if the child has a history of severe bleeding. The answer is no. So they look completely asymptomatic on paper. Right. But this child has never had a dental extraction. They've never had major surgery. They've never been in a severe accident. Aaron Powell, Jr.

SPEAKER_00 11:54

And that context changes everything. A mild VWF reduction of 42 means something entirely different in a person who has endured heavy menstrual bleeding, postpartum hemorrhage, and prolonged bleeding after dental work versus someone who has no symptoms at all, even though the number is identical.

SPEAKER_01 12:10

The number on the lab report might be identical, yes. But the underlying probability of them harboring a significant bleeding disorder is drastically different.

SPEAKER_00 12:18

One person has been repeatedly tested by life and the other hasn't even stepped up to the plate yet.

SPEAKER_01 12:23

Exactly. Bleeding scores and standardized questionnaires are helpful tools, sure, but they are inherently flawed because they depend entirely on the opportunity to bleed.

SPEAKER_00 12:34

That is such a wild concept, the opportunity to bleed.

SPEAKER_01 12:37

A bleeding phenotype isn't merely a checklist of symptoms. It is a historical record of encounters between a person's hemostatic reserve, which is the biological capacity of their blood to clot, and their hemostatic demand.

SPEAKER_00 12:51

Meaning the physical injuries, surgeries, or biological events life is thrown at them.

SPEAKER_01 12:56

Right. So a clinician looking at an asymptomatic patient has to figure out exactly why there are no symptoms.

SPEAKER_00 13:03

They have to play detective again.

SPEAKER_01 13:04

They must make a careful, highly analytical distinction. They have to differentiate between no bleeding, despite meaningful challenges, which significantly lowers the probability of an underlying disease. And no bleeding, because meaningful challenges have not occurred.

SPEAKER_00 13:20

Which is like, you know, you cannot declare a bridge structurally sound simply because a heavy semi-truck hasn't driven over it yet.

SPEAKER_01 13:28

That's a great way to put it.

SPEAKER_00 13:29

If the bridge hasn't borne weight, you don't actually know if it's safe. You just preserve the uncertainty.

SPEAKER_01 13:34

And the uncertainty remains intact until the hemostatic demand is applied.

SPEAKER_00 13:38

Man. As if messy biology or circumstantial history weren't enough of a headache for a medical detective. There is another variable that fundamentally alters the investigation. Time.

SPEAKER_01 13:49

Ah, yes. Time.

SPEAKER_00 13:52

What happens when the simple passage of time literally changes the evidence?

SPEAKER_01 13:56

This is one of the most counterintuitive dynamics of the borderland. VWF levels often rise as a person ages.

SPEAKER_00 14:03

Wait, really? So a patient could be officially diagnosed with type 1 VWD in their 20s when their levels are low, but when they are retested in their 50s, their levels might read as completely normal?

SPEAKER_01 14:12

Yes. The evidence essentially vanishes.

SPEAKER_00 14:15

The disease exists on paper and then it doesn't.

SPEAKER_01 14:17

Which forces a profound philosophical and clinical question. Does the diagnosis disappear? Did the patient cure their von Willebrand disease? Or did the lab value simply undergo a natural age-related shift due to changes in their blood vessels or underlying inflammation?

SPEAKER_00 14:35

How does a clinician even handle a patient whose current blood work contradicts their medical history like that?

SPEAKER_01 14:41

Well, the clinical reality must remain grounded in the phenotype. The current VWF level matters immensely for immediate management.

SPEAKER_00 14:48

So if a patient is having surgery today.

SPEAKER_01 14:50

The surgeon needs to know the clotting capacity of the blood today, but the historical phenotype matters for the interpretation of the disease.

SPEAKER_00 14:58

Okay, that makes sense.

SPEAKER_01 14:58

If a patient presents a normal VWF value at age 50, that single data point does not erase a lifelong documented history of postpartum hemorrhage, severe iron deficiency, or heavy menses.

SPEAKER_00 15:11

So what does this all mean? Let's bring up a specific case study from the text to ground this. Think about a 42-year-old woman who walks into a clinic. She has a documented history of heavy menses since she was a teenager. She experienced a terrifying postpartum hemorrhage after delivering her first child, and she had prolonged, difficult-to-control bleeding after getting her wisdom teeth extracted in her 20s.

SPEAKER_01 15:32

So going back to your analogy, the bridge has been heavily tested by semitrucks and it has visibly struggled to hold the weight every single time.

SPEAKER_00 15:39

Exactly. Her hemostatic demand has repeatedly overwhelmed her hemostatic reserve. Now, she gets her VWF levels tested twice by her current doctor.

SPEAKER_01 15:48

And what do they show?

SPEAKER_00 15:49

The results come back at 42 and 46 IUDL. Her multi-MERS, those massive sticky chains, are structurally totally normal. Genetic sequencing reveals no obvious identifiable pathogenic variant, so there's no glaring mutation they can point to. Right. Based on all the shifting rules of the borderland, what is her actual diagnosis?

SPEAKER_01 16:09

If we connect this to the bigger picture, under the 2021 guidelines from the Hematology Coalition, because her levels fall below 50 and she possesses a clear history of abnormal bleeding, she officially receives the diagnosis of type 1 VWD. Yet, if a clinician were applying older medical frameworks or viewing her strictly through a mechanistic lens, she might just be told she has low VWF and then be dismissed.

SPEAKER_00 16:35

Which highlights the absurdity of arguing over the semantic label, doesn't it? I mean the label itself isn't the point.

SPEAKER_01 16:40

No, the semantic label matters far less than the function that label serves. In the borderland, the purpose of classification is to organize the probability of her future bleeding risk. Right. If this 42-year-old woman requires an abdominal surgery tomorrow, her clinical team needs a structured way to conceptualize her risk and prepare the necessary hemostatic therapies. The diagnosis is a tool to organize probability, synthesizing her history, her repeated lab tests, her age, and even her blood type.

SPEAKER_00 17:10

And regarding blood type, the current guidelines are very clear that clinicians should not use demographic reference ranges to just wave away a patient's symptoms.

SPEAKER_01 17:18

That's a crucial point.

SPEAKER_00 17:19

Because it is a known fact that people with typo blood naturally have lower VWF levels. But if a woman with typo blood is hemorrhaging, you don't dismiss her suffering by saying, well, you know, that's just normal for typo. If she is bleeding, she is bleeding.

SPEAKER_01 17:35

Exactly. You cannot dismiss real-world clinical realities simply because a demographic chart offers a convenient excuse. The diagnosis synthesizes all available variables to manage risk in the real world.

SPEAKER_00 17:47

So bringing it all together, airge classification at the border reveals that while the Center of Medicine relies on naming discrete mechanical failures, the border requires profound clinical judgment.

SPEAKER_01 17:59

It's a delicate, continuous balancing act.

SPEAKER_00 18:01

It requires avoiding the reflex to over-medicalize normal biological variation, while simultaneously avoiding the reflex to underdiagnose and ignore a patient's actual suffering just because their lab numbers don't look dramatic enough on a piece of paper.

SPEAKER_01 18:14

Absolutely. The borderland demands that clinicians tolerate uncertainty. And I actually want to leave you, the listener, with one final thought regarding this continuous biological gradient.

SPEAKER_00 18:23

Okay, let's hear it.

SPEAKER_01 18:24

We rely on these diagnostic thresholds right now because they act as artificial dams, helping us pool information and make binary treatment decisions in a really complex world.

SPEAKER_00 18:33

Right, because we need those lines in the sand.

SPEAKER_01 18:35

But how long will those dams be necessary? Imagine a near future where artificial intelligence and continuous biometric tracking can map your unique biological gradient in real time.

SPEAKER_00 18:46

Oh wow.

SPEAKER_01 18:47

If we eventually possess the technology to monitor a patient's hemostatic reserve continuously rather than relying on a static snapshot from a single blood draw, could the medical borderland eventually disappear entirely?

SPEAKER_00 19:01

That is wild to think about. We might eventually move past the need for checkboxes altogether. The fingerprints won't be a mystery if we can just watch them change in real time.

SPEAKER_01 19:09

Exactly.

SPEAKER_00 19:10

Well, thank you for joining us on this deep dive. Your curiosity is what drives these explorations. Keep asking questions, keep looking past the obvious labels, and we will catch you on the next one.